INTERIM RESULTS FROM A SINGLE-ARM MULTICENTER PHASE II TRIAL OF CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)

被引：2
|
作者：
Packiam, Vignesh T.
Barocas, Daniel A.
Chamie, Karim
Davis, Ronald L., III
Kader, A. Karim
Lamm, Donald L.
Curran, Dominic
Yeung, Alex W.
Steinberg, Gary D.
机构：
来源：
JOURNAL OF UROLOGY | 2017年 / 197卷 / 04期
关键词：
D O I：
10.1016/j.juro.2017.03.039
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PNFLBA-13
引用
收藏
页码：E915 / E916
页数：2
相关论文
共 50 条
  • [41] A multicenter clinical trial of intravesical BCG in combination with ALT-803 in patients with BCG-unresponsive non-muscle invasive bladder cancer.
    Chamie, Karim
    Salmasi, Amirali
    Rosser, Charles Joel
    Rock, Amy
    Ferguson, Lydia
    Wong, Hing C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [42] Interim results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).
    Li, Zhiyong
    He, Liru
    Yao, Kai
    Ye, Yunlin
    Li, Xiangdong
    Qin, Zike
    Han, Hui
    Zhou, Fangjian
    Liu, Zhuowei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] PHASE 3 STUDY OF VICINEUM IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER: 24-MONTH RESULTS
    O'Donnell, Michael
    Shore, Neal
    Keane, Thomas
    Jewett, Michael
    Dickstein, Rian
    Wolk, Fred
    Dillon, Rachelle L.
    Cizeau, Jeannick
    Kassouf, Wassim
    JOURNAL OF UROLOGY, 2021, 206 : E296 - E297
  • [44] Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial
    Mitra, Anirban P.
    Narayan, Vikram M.
    Mokkapati, Sharada
    Miest, Tanner
    Boorjian, Stephen A.
    Alemozaffar, Mehrdad
    Konety, Badrinath R.
    Shore, Neal D.
    Gomella, Leonard G.
    Kamat, Ashish M.
    Bivalacqua, Trinity J.
    Montgomery, Jeffrey S.
    Lerner, Seth P.
    Busby, J. Erik
    Poch, Michael
    Crispen, Paul L.
    Steinberg, Gary D.
    Schuckman, Anne K.
    Downs, Tracy M.
    Svatek, Robert S.
    Mashni, Joseph
    Lane, Brian R.
    Guzzo, Thomas J.
    Bratslavsky, Gennady
    Karsh, Lawrence, I
    Woods, Michael E.
    Brown, Gordon A.
    Canter, Daniel
    Luchey, Adam
    Lotan, Yair
    Krupski, Tracey
    Inman, Brant A.
    Williams, Michael B.
    Cookson, Michael S.
    Keegan, Kirk A.
    Andriole, Gerald L.
    Sankin, Alexander, I
    Boyd, Alan
    O'Donnell, Michael A.
    Philipson, Richard
    Yla-Herttuala, Seppo
    Sawutz, David
    Parker, Nigel R.
    McConkey, David J.
    Dinney, Colin P. N.
    EUROPEAN UROLOGY, 2022, 81 (03) : 223 - 228
  • [45] Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicenter, Phase 2 Study
    Rentsch, Cyrill A.
    Hayoz, Stefanie
    Cathomas, Richard L.
    EUROPEAN UROLOGY, 2022, 81 (05) : 542 - 542
  • [46] Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial
    Funt, Samuel A.
    Lattanzi, Michael
    Whiting, Karissa
    Al-Ahmadie, Hikmat
    Quinlan, Colleen
    Teo, Min Yuen
    Lee, Chung-Han
    Aggen, David
    Zimmerman, Danielle
    McHugh, Deaglan
    Apollo, Arlyn
    Durdin, Trey D.
    Truong, Hong
    Kamradt, Jeffrey
    Khalil, Maged
    Lash, Bradley
    Ostrovnaya, Irina
    McCoy, Asia S.
    Hettich, Grace
    Regazzi, Ashley
    Jihad, Marwah
    Ratna, Neha
    Boswell, Abigail
    Francese, Kaitlyn
    Yang, Yuanquan
    Folefac, Edmund
    Herr, Harry W.
    Donat, S. Machele
    Pietzak, Eugene
    Cha, Eugene K.
    Donahue, Timothy F.
    Goh, Alvin C.
    Huang, William C.
    Bajorin, Dean F.
    Iyer, Gopa
    Bochner, Bernard H.
    Balar, Arjun V.
    Mortazavi, Amir
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (12) : 1312 - +
  • [47] FINAL CLINICAL RESULTS OF PIVOTAL TRIAL OF IL-15RAFC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CIS AND PAPILLARY COHORTS
    Chang, Sam
    Chamie, Karim
    Hidalgo, Mark
    Kramolowsky, Eugene
    Sexton, Wade
    Reddy, Sandeep
    Soon-Shiong, Patrick
    JOURNAL OF UROLOGY, 2022, 207 (05): : E1047 - E1047
  • [48] Subgroup analyses of the phase 3 study of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
    Narayan, V.
    Boorjian, S.
    Alemozaffer, M.
    Konety, B. R.
    Gomella, L.
    Kamat, A. M.
    Lerner, S. P.
    Svatek, R. S.
    Karsh, L.
    Canter, D.
    Lotan, Y.
    Inman, B. A.
    Yang, M.
    Garcia-Horton, V.
    Sawutz, D.
    Parker, N.
    Dinney, C. P. N.
    EUROPEAN UROLOGY, 2021, 79 : S1026 - S1027
  • [49] Preliminary phase 2 clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients.
    Chamie, Karim
    Lee, John H.
    Rock, Amy
    Rhode, Peter R.
    Soon-Shiong, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] Phase II/III clinical results of IL-15R[alpha]Fc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients.
    Chamie, Karim
    Chang, Sam
    Gonzalgo, Mark L.
    Kramolowsky, Eugene, V
    Sexton, Wade J.
    Reddy, Sandeep K.
    Bhar, Paul
    Garner, Chad
    Soon-Shiong, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345